Posted by Michael Wonder on 16 Dec 2016
Trump's FDA chief may implement progressive approval for drugs
15 December 2016 - The first potential FDA chief appointee leaked by the Trump transition team is Jim O’Neill.
Managing director of Peter Thiel’s Mithril Capital, O’Neill has publicly supported proposals to do away with the FDA’s requirement for phase 2 and 3 trials. Instead, he favours “progressive approval” of drugs and other medical technologies.
O’Neill would not be the first FDA head to favour progressive drug approval. Andrew von Eschenbach developed this system when he served as FDA chief. But during his tenure, Eschenbach was not able to put such a far-reaching reform into practice in the US.
